```html

Neuro‑lupus (Nervous System Lupus) – Comprehensive Medical Guide

Overview

Neuro‑lupus is the term used when systemic lupus erythematosus (SLE) – an autoimmune disease that can affect any organ – involves the central or peripheral nervous system. The inflammation can damage the brain, spinal cord, cranial nerves, and peripheral nerves, leading to a wide array of neurological and psychiatric manifestations.

• Who it affects: Primarily women (≈90% of SLE cases), most often between ages 15‑45. However, men, children, and older adults can develop neuro‑lupus.
• Prevalence: Roughly 10‑30% of people with SLE experience neurological involvement during their lifetime.1 Population‑based studies estimate an overall prevalence of SLE around 20–150 per 100,000, meaning neuro‑lupus affects roughly 2–45 per 100,000 people worldwide.
• Why it matters: Neurological complications are a leading cause of morbidity and mortality in SLE, accounting for up to 20% of SLE‑related deaths.2 Early recognition and treatment can dramatically improve outcomes.

Symptoms

Neuro‑lupus can present with a wide spectrum of symptoms, reflecting the part of the nervous system that is involved. Below is a comprehensive list, grouped by system.

Central Nervous System (CNS) manifestations

• Headache – often severe, can be migrainous or tension‑type.
• Cognitive dysfunction (“lupus fog”) – difficulty concentrating, memory lapses, slower processing speed.
• Seizures – focal or generalized; present in ~10‑20% of neuro‑lupus patients.
• Stroke or transient ischemic attack (TIA) – due to vasculitis or antiphospholipid antibodies.
• Psychiatric symptoms – depression, anxiety, psychosis, mood swings, or personality changes.
• Movement disorders – chorea, tremor, or ataxia.
• Encephalitis – inflammation of brain tissue causing fever, confusion, and seizures.
• Demyelinating lesions – may mimic multiple sclerosis on MRI.
• Peripheral optic neuritis – vision loss or blurring.

Peripheral Nervous System (PNS) manifestations

• Peripheral neuropathy – numbness, tingling, burning, or weakness in hands/feet.
• Mononeuritis multiplex – sudden loss of function in two or more isolated nerves.
• Guillain‑Barré‑like syndrome – ascending weakness and areflexia.
• Myelitis – inflammation of the spinal cord causing sensory loss, weakness, and bladder dysfunction.

Autonomic dysfunction

• Orthostatic hypotension, abnormal sweating, gastrointestinal dysmotility, or urinary retention.

Causes and Risk Factors

Neuro‑lupus is not a separate disease; it is a manifestation of the systemic auto‑immune process of SLE. The exact mechanisms are complex and involve several pathways.

Underlying mechanisms

• Autoantibody‑mediated injury – Antibodies such as anti‑NMDAR, anti‑ribosomal P, and antiphospholipid antibodies can cross the blood‑brain barrier (BBB) and attack neuronal tissue.
• Immune complex deposition – Circulating antigen‑antibody complexes lodge in cerebral vessels, causing vasculitis and ischemia.
• Complement activation – Triggers inflammation and tissue damage.
• Blood‑brain barrier disruption – Cytokines (IL‑6, TNF‑α) increase permeability, allowing immune cells into the CNS.
• Thrombotic events – Antiphospholipid syndrome (APS) leads to clot formation, precipitating stroke.

Risk factors

• Female sex (especially African‑American, Hispanic, and Asian women).
• Early onset SLE (diagnosed before age 30).
• High disease activity (SLEDAI score ≥6).
• Presence of antiphospholipid antibodies or diagnosed APS.
• History of severe organ involvement (e.g., lupus nephritis, serositis).
• Smoking, hypertension, hyperlipidemia – these amplify vascular risk.
• Genetic predisposition – HLA‑DR2/DR3 alleles linked to neuro‑lupus.

Diagnosis

Because neuro‑lupus mimics many other neurological disorders, a systematic approach is essential.

Clinical evaluation

• Detailed history – onset, pattern, triggers, other SLE manifestations.
• Neurological examination – cranial nerves, motor strength, sensation, reflexes, coordination, gait.
• Psychiatric assessment – mood, cognition, psychosis.

Laboratory tests

• Antinuclear antibody (ANA) – positive in >95% of SLE patients.
• Anti‑dsDNA, anti‑Smith (Sm) – correlate with disease activity.
• Antiphospholipid antibodies (lupus anticoagulant, anticardiolipin, β2‑glycoprotein I) – assess thrombotic risk.
• Complement levels (C3, C4) – low levels suggest active immune complex disease.
• Inflammatory markers – ESR, CRP (may be modestly elevated).
• CSF analysis (if encephalitis, meningitis, or severe headache): elevated protein, lymphocytic pleocytosis, oligoclonal bands in some cases.

Imaging studies

• MRI of brain and spine – preferred imaging; looks for white‑matter hyperintensities, cortical atrophy, infarcts, or demyelinating lesions.
• MR angiography/CT angiography – evaluates vasculitis or thrombosis.
• Functional imaging (PET, SPECT) – may show hypometabolism in affected regions, useful in research settings.

Neurophysiology

• Electroencephalography (EEG) – detects seizure activity, diffuse slowing.
• Nerve conduction studies & EMG – assess peripheral neuropathy or myelitis.

Diagnostic criteria

There is no universally accepted set of criteria solely for neuro‑lupus. Clinicians generally use the 1999 American College of Rheumatology (ACR) criteria for SLE combined with “clinical attribution” – ruling out alternative causes (infection, medication toxicity, primary psychiatric disease).

Treatment Options

Treatment is individualized, targeting the underlying autoimmune activity, specific neurological complications, and any co‑existing vascular risk factors.

First‑line immunosuppression

• Corticosteroids – high‑dose oral prednisone (0.5‑1 mg/kg/day) or IV methylprednisolone pulses (e.g., 1 g daily for 3 days) for acute flares.
• Antimalarials (Hydroxychloroquine) – recommended for all SLE patients; modestly reduces neuro‑lupus activity and improves survival.3

Steroid‑sparing agents

• Azathioprine – 2‑2.5 mg/kg/day; useful for maintenance after acute control.
• Mycophenolate mofetil (MMF) – 1‑1.5 g twice daily; effective for CNS vasculitis and lupus nephritis.
• Cyclophosphamide – IV pulses (e.g., 0.5‑1 g/m²) for severe CNS involvement such as fulminant vasculitis, transverse myelitis, or refractory seizures.
• Rituximab – anti‑CD20 monoclonal antibody; considered in refractory cases or when patients cannot tolerate cyclophosphamide.
• Belimumab – BAFF inhibitor; approved for SLE, may reduce neuro‑lupus activity in some patients.

Targeted therapy for specific complications

• Anticoagulation – warfarin (INR 2‑3) or direct oral anticoagulants for APS‑related stroke or TIA.
• Antiepileptic drugs (AEDs) – levetiracetam, valproic acid, or lamotrigine for seizure control.
• Antidepressants/psychotropics – SSRIs, SNRIs, or atypical antipsychotics for mood or psychosis.
• Plasma exchange – reserved for life‑threatening, antibody‑mediated encephalitis not responding to steroids.

Lifestyle and supportive measures

• Sun protection – UV exposure can flare SLE.
• Regular cardiovascular risk screening – blood pressure, lipids, glucose.
• Physical therapy – maintain strength, balance, and gait.
• Occupational therapy – strategies for cognitive difficulties.
• Vaccinations – influenza, pneumococcal, HPV; avoid live vaccines while on high‑dose immunosuppression.

Living with Nervous System Lupus (Neuro‑lupus)

Managing neuro‑lupus is a partnership between the patient, rheumatologist, neurologist, and allied health professionals.

Daily management tips

1. Medication adherence – Use pill organizers or smartphone reminders; never stop steroids abruptly.
2. Track symptoms – Keep a daily log of headaches, mood, cognition, and new neurological signs; share with your care team.
3. Healthy sleep hygiene – Aim for 7‑9 hours; sleep disorders worsen fatigue and cognition.
4. Balanced diet – Mediterranean‑style diet rich in omega‑3 fatty acids, antioxidants, and low in saturated fats helps reduce inflammation.
5. Exercise safely – Low‑impact activities (walking, swimming, yoga) improve circulation and mood; consult physio before starting.
6. Stress reduction – Mindfulness, meditation, or counseling can mitigate flare triggers.
7. Regular monitoring – Quarterly labs (CBC, electrolytes, kidney function, complement, dsDNA) and annual neurologic assessment.
8. Support networks – Join lupus patient groups, either in‑person or online, for emotional support and shared coping strategies.

Work and school considerations

• Request reasonable accommodations (extra breaks, flexible hours) if fatigue or cognitive fog interferes.
• Inform employers/teachers about potential seizure risk and necessary emergency plans.
• Consider tele‑work or remote learning during active flares.

Prevention

Because neuro‑lupus is a manifestation of SLE, “prevention” focuses on minimizing overall disease activity and managing modifiable risk factors.

• Maintain strict control of SLE with disease‑modifying therapy (hydroxychloroquine is cornerstone).
• Quit smoking – smoking doubles the risk of severe lupus flares.
• Control hypertension, diabetes, and hyperlipidemia – reduces stroke risk.
• Avoid excessive sun exposure; use SPF 30+ sunscreen daily.
• Promptly treat infections – infections can trigger immune activation.
• Regular ophthalmology exams – early detection of hydroxychloroquine retinopathy allows safe continuation of therapy.

Complications

If neuro‑lupus is not adequately treated, serious complications can arise:

• Permanent cognitive deficits – lasting memory loss, executive dysfunction.
• Recurrent strokes – leading to progressive disability.
• Severe seizures – status epilepticus, which can be life‑threatening.
• Chronic neuropathic pain – impairing quality of life.
• Psychiatric disorders – major depression, psychosis, or suicidal ideation.
• Mobility loss – from myelitis or severe peripheral neuropathy.
• Increased mortality – neuro‑lupus contributes to the higher death rate seen in SLE patients.

When to Seek Emergency Care

---

References: 1. Hanly JG et al. “Neuro‑psychiatric complications of systemic lupus erythematosus.” Lupus. 2020;29(9):1150‑1164. 2. Urowitz MB et al. “Mortality in systemic lupus erythematosus: Trends over 50 years.” Arthritis Rheum. 2015;67(5):1315‑1323. 3. Rovin BH et al. “Hydroxychloroquine in lupus: A systematic review.” JAMA Dermatol. 2022;158(2):185‑193. CDC. Systemic Lupus Erythematosus (SLE) Fact Sheet. Mayo Clinic. “Neuro‑lupus.” Accessed May 2026. NIH National Institute of Arthritis and Musculoskeletal and Skin Diseases. World Health Organization. “Lupus and the nervous system.”

```